Result of GM
Summary by AI BETAClose X
Renalytix plc
(“Renalytix” or the “Company”)
Result of General Meeting
LONDON and NEW YORK, 28 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that at the General Meeting (“GM”) held earlier today, all resolutions were passed. Further details of each of the resolutions are set out in the Circular that contains the Notice of General Meeting, which was sent to the Company’s shareholders on 8 September 2026.
The results of the GM are detailed below:
|
|
In favour |
|
|
Against |
|
|
Withheld |
|
Resolution |
Votes |
% |
|
Votes |
% |
|
Votes |
|
1 |
369,271,285 |
99.86 |
|
511,888 |
0.14 |
|
27,682 |
|
2 |
368,948,416 |
99.77 |
|
833,907 |
0.23 |
|
28,532 |
James McCullough, CEO of Renalytix, commented:
“I would like to thank our existing and new shareholders for their strong support of the Company through the recently completed capital raise. With the financing now complete and a significantly strengthened balance sheet, including eliminating all convertible debt, we are well positioned to execute on our commercial plans. We look forward to providing further updates on our progress in the coming months.”
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for the admission to trading on AIM for the 7,500,000 Second Tranche Placing Shares, the 52,792,950 Subscription Shares and the 6,335,707 Retail Offer Shares (the ‘Second Tranche Shares’) ('Admission'). It is expected that Admission of the Second Tranche Shares will become effective and that trading will commence in the Second Tranche Shares at 8.00 a.m. on 29 September 2026. The Second Tranche Shares will rank pari passu with the Company's existing Ordinary Shares.
Following Admission, the total issued share capital of the Company will consist of 670,459,333 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 670,459,333 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Capitalised terms not defined have the same meaning as given to them in the Company's Circular dated 8 September 2026.
For further information, please contact:
|
Renalytix plc |
||
|
James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
|
|
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker) |
Tel: +44 (0)20 3470 0470 |
|
|
David Hignell / Jen Clarke (Corporate Finance) |
|
|
|
Vadim Alexandre (Corporate Broking) |
|
|
|
|
|
|
|
Oberon Capital (Joint Broker) |
Tel: +44 (0)20 3179 5300 |
|
|
Mike Seabrook / Nick Lovering |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About Renalytix (www.renalytix.com)
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.
Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom’s medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare-reimbursed prognostic tool capable of understanding a patient’s risk with diabetic kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.
The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).
KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX,dkd test, visit kidneyintelx.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 14 hours ago Savannah Energy
- 15 hours ago Buccaneer Energy PLC
- 15 hours ago Savannah Energy
- 15 hours ago Carclo
- 16 hours ago Schroder Japan Growth Fund